FDA APPROVES NOVOLOG FOR TREATMENT OF DIABETES IN CHILDREN
Novo Nordisk has announced that the FDA has approved the supplemental new drug application of NovoLog (insulin aspart [rDNA origin] injection) for the treatment of diabetes in children.
NovoLog is a rapid-acting insulin analogue that can be administered immediately before a meal. The FDA approval comes approximately four months before the agency's review deadline. The drug was studied for use in children and adolescents with diabetes ranging in age from two to 18. In these studies, NovoLog was found to be both safe and effective.